Outcomes

van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and structural damage inhibition in patients with psoriatic arthritis (PsA).

This pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and for every modality tested.

The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less apnea–hypopnea events in participants with obstructive sleep apnea.

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with education compared to single education and self-directed

Obesity is an incidental comorbidity in psoriatic arthritis (PsA). It is a modifiable, mechanistically active driver of disease onset, severity, and treatment failure. A new comprehensive review in RMD Open (Madsen et al., 2026) synthesizes 49 studies suggesting that weight management belongs in

The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of incident rheumatoid arthritis (RA), but not psoriasis.